Participating Faculty: Economic Considerations for the Treatment of Opioid and Alcohol Dependence

Economic Considerations for the Treatment of Opioid and Alcohol Dependence

This supplement to The American Journal of Managed Care reports the results of several studies analyzing the impact of pharmacologic treatment for alcohol or opioid dependence on costs and utilization. Described within are the results from 3 retrospective studies in alcohol dependence and 1 in opioid dependence that used data from several claims databases. Although further research is necessary, these results may help managed care organizations identify cost-effective therapies which may improve outcomes.

Faculty

Onur Baser, MS, PhD

STATinMED Research and the University of Michigan

Ann Arbor, Michigan

Ami S. Borawala, PharmD

Rutgers, The State University of New Jersey

Piscataway, New Jersey

Horizon Blue Cross Blue Shield of New Jersey

Newark, New Jersey

William C. Bryson, MD, MPH

Duke University School of Medicine

Durham, North Carolina

Department of Public Health and Preventive Medicine

Oregon Health and Sciences University

Portland, Oregon

Mady Chalk, PhD

Treatment Research Institute

Philadelphia, Pennsylvania

David A. Fiellin, MD

Yale University School of Medicine

New Haven, Connecticut

David R. Gastfriend, MD

Alkermes, Inc

Waltham, Massachusetts

Patrick Gill, RPh

Manager, Pharmacy Administration

Horizon Blue Cross Blue Shield of New Jersey

Newark, New Jersey

Saira Jan, PharmD

Director of Clinical Pharmacy Management

Horizon Blue Cross Blue Shield of New Jersey

Newark, New Jersey

Clinical Professor

Ernest Mario School of Pharmacy

Rutgers, The State University of New Jersey

Piscataway, New Jersey

P. Todd Korthuis, MD, MPH

Departments of Public Health and Preventive Medicine and Internal Medicine

Oregon Health and Sciences University

Portland, Oregon

Dennis McCarty, PhD

Department of Public Health and Preventive Medicine

Oregon Health and Sciences University

Portland, Oregon

K. John McConnell, PhD

Department of Emergency Medicine

Oregon Health and Sciences University

Portland, Oregon

Richard Rawson, PhD

University of California, Los Angeles Integrated Substance Abuse Programs

Los Angeles, California

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Dennis McCarty, PhD

Consultant: Purdue Pharma

Research grants: National Institutes of Health (pending)

David A. Fiellin, MD

Honoraria: Pinney Associates

David R. Gastfriend, MD

Employee: Alkermes, Inc

Stock ownership: Alkermes, Inc

Onur Baser, MS, PhD; Ami S. Borawala, PharmD; William C. Bryson, MD, MPH; Mady Chalk, PhD; Patrick Gill, RPh; Saira Jan, PharmD; P. Todd Korthuis, MD, MPH; K. John McConnell, PhD; and Richard Rawson, PhD, have nothing to disclose.

This supplement was supported by Alkermes, Inc.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.